The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates

British Journal of Pharmacology

Volumn 129, Issue 7, 2000, Pages 1355-1364

  Treseder, Sarah A ^a   Jackson, Michael ^a   Jenner, Peter ^a,b  

^a Neurodeg Diseases Research Centre   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antiparkinsonian activity; Central aromatic amino acid DOPA decarboxylase; Dopamine agonists; L DOPA; Marmosets; MPTP

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 HYDROXYBENZYLHYDRAZINE; 4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; QUINPIROLE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; LOCOMOTION; MARMOSET; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MUSCLE TONE; NONHUMAN; PRIMATE; PRIORITY JOURNAL;

EID: 0034030139     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703189     Document Type: Article

References (65)

1. 3H] gamma-aminobutyric acid in the basal ganglia of 6-OHDA lesioned rats. Neurosci. Lett., 121, 223-226.
2. Akai, T., Ozawa, M., Yamaguchi, M., Mizuta, E. & Kuno, S. (1995). Behavioral involvement of central dopamine D-1 and D-2 receptors in 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned Parkinsonian cynomolgus monkeys. Jap. J. Pharmacol., 67, 117-124.
3. Bedard, P.J., Gomez-Mancilla, B., Blanchet, P., Calon, F., Grondin, R., Gagnon, C., Falardeau, P., Goulet, M., Morissette, M., Rouillaerd, C. & Paolo, T.D. (1997). Dopamine agonists as first line therapy of Parkinsonism in MPTP monkeys. In: Beyond the Decade of the Brain. Olanow C. W. and Obeso J.A. (eds.). Royal Tunbridge Wells, Wells Medical Limited. 2, 101-113.
4. Bernheimer, H., Birkmayer, W. & Hornykiewicz, O. (1963). Zur Biochemie des Parkinson-Syndroms des Menschen. Klin. Wschr., 41, 465-469.
5. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. (1965). Zur Differenzierung des Parkinson-Syndroms: Biochemisch-Neurohistolisch Vergleichsunterssuchungen. In: Proc. 8th Inter. Congress of Neurology, Vienna. Wiener Medizinische Akademie.
6. Björklund, A., & Lindvall, O. (1984). In: Handbook of Chemical Neuroanatomy, 2, Classical Transmitters in the CNS, Part 1, Dopamine containing systems in the CNS. Björkland, A. & Hökfelt, T. (eds.). Amsterdam, Elsevier, pp. 55-122
7. Blanchet, P., Bedard, P.J., Britton, D.R. & Kebabian, J.W. (1993). Differential effect of selective D-1-dopamine and D-2-dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J. Pharmcol. Exp. Therapeut., 267, 275-279.
8. Brunnerguenat, M., Carrupt, P. A., Lisa, G., Testa, B., Rose, S., Thomas, K., Jenner, P. & Ventura, P. (1995). Esters of L-Dopa structure-hydrolosis relationships and ability to induce circling behaviour in an experimental-model of Hemiparkinsonism. J. Pharm. Pharmacol., 47, 861-869.
9. Butcher, L.L., Engel, J. & Fuxe, K. (1972). Behavioural, biochemical and histological analysis of the effects of monoamine precursors after peripheral decarboxylase inhibition. Brain Research, 41, 387-411.
10. Crescimanno, G., Emmi, A. & Amato, G. (1998). Effects of intraacumbens microinjections of quinpirole on head turning and circling movement in the rat. Pharmacology Biochemistry and Behavior, 60, 829-834.
11. Dolphin, A.C., Jenner, P. & Marsden, C.D. (1975). The relative importance of domamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or a-methyl-p-tyrosine pre-treated mice. Pharm. Biochem. Behav., 4, 661-670.
12. Dziewczapolski, G., Mora, M.A., Menalled, L.B., Stefano, F.J.E., Rubinstein, M. & Gershanik, O.S. (1997). Threshold of dopamine content and D-1 receptor stimulation necessary for the expression of rotational behaviour induced by D-2 receptor stimulation under normo and supersensitive conditions. Naunyn-Schmiedebergs Arch. Pharmacol., 355, 30-35.
13. Eden, R., Costall, B., Domeney, A., Gerrard, P., Harvey, C. & Kelly, M. (1991). Preclinical pharmacology of ropinirole (SK-AND-F-101468-A) a novel dopamine-D2 agonist. Pharm. Biochem. Behav., 38, 147-154.
14. Ehringer, H. & Hornykiewicz, O. (1960). Verteilung von Noradrenaline und Dopamin (3-Hydroxytyramine) in Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin. Wschr., 38, 1236-1239.
15. Elliott, P.J., Walsh, D.M. & Close, S.P. (1992). Dopamine-D1 and D2 receptor interactions in the MPTP-treated marmoset. Neurosci. Lett., 142, 1-4.
16. Gershanik, O., Heikkila, R.E. & Duvoisin. R.C. (1983). Effects of dopamine depletion on rotational behavior to dopamine agonists. Brain Res., 261, 358-360.
17. Gnanalingham, K.K., Milkowski, N.A., Smith, L.A., Hunter, A.J., Jenner, P. & Marsden, C.D. (1995). Short-Term and Long-Term Changes in Striatal and Extrastriatal Dopamine uptake sites in the MPTP-treated common marmoset. Eur. J. Pharmacol., 277, 235-241.
18. Gomez-Mancilla, B. & Bedard, P.J. (1991). Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Therap., 259, 409-413.
19. Gomez-Mancilla, B. & Bedard, P.J. (1993). Effect of nondopaminergic drugs On L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418-427.
20. Goshima, Y., Nakamura, S. & Misu, Y. (1990). L-DOPA facilitates the release of endogenous norepinephrine and dopamine via presynaptic B1 and B2-adrenoceptors under essentially complete inhibition of L-aromatic amino acid decarboxylase in rat hypothalamic slices. Jap. J. Pharmacol., 53, 47-56.
21. Goshima, Y., Ohno, K., Nakamura, S., Miyamae, T., Misu, Y. & Akaike, A. (1993). L-DOPA induces Ca2+ -dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices. Brain Res., 617, 167-170.
22. Grondin, R., Bedard, P.J., Britton, D.R. & Shiosaki, K. (1997). Potential therapeutic use of the selective dopamin D-1 receptor agonist, A-86929: An acute study in Parkinsonian levodopa-primed monkeys. Neurology, 49, 421-426.
23. Hagan, J.J., Middlemiss, D.N., Sharpe, P.C. & Poste, G.H. (1997). Parkinson's disease: Prospects for improved drug therapy. Trends Pharmacol. Sci., 18, 156-163.
24. Hornykiewicz, O. (1974). The mechanisms of action of L-DOPA in Parkinson's disease. Life Sci., 15, 1249-1259.
25. Jenner, P. (1995). The rationale for the use of dopamine agonists in Parkinsons-disease. Neurology, 45, 6-12.
26. Jenner, P., Rupniak, N.M.J., Rose, S., Kelly, E., Kilpatrick, G., Lees, A. & Mardsen, C.D. (1984). 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced Parkinsonism in the common marmoset. Neurosci Lett., 50, 85-90.
27. Jones, G. & Robbins, T. (1992). Differential-effects of mesocortical, mesolimbic, and mesostriatal dopamine depletion on spontaneous, conditioned, and drug-induced locomotor-activity. Pharmacol. Biochem. Behav., 43, 887-895.
28. Kaakkola, S., Tuomainen, P., Wurtman, R.J. & Mannisto, P.T. (1992). Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum. J. Neur. Trans-Parkinsons Disease and Dementia Section, 4, 143-154.
29. Kebabian, J.W., Britton, D.R., Deninno, M.P., Perner, R., Smith, L., Jenner, P., Schoenleber, R. & Williams, M. (1992). A-77636 - a potent and selective dopamine-D1 receptor agonist with anti-Parkinsonian activity in marmosets. Eur. J. Pharmacol., 229, 203-209.
30. Kebabian, J.W. & Calne, D.B. (1979). Multiple receptors for dopamine. Nature, 277, 93-96.
31. Keyser, J.D., Backer, J.D., Wilczak, N. & Herroelen, L. (1995). Dopamine Agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in the human striatum. Neur. Psychopharmacol. Biol. Psychiat., 19, 1147-1154.
32. Lindskog, M., Svenningsson, P., Fredholm, B., Greengard, P. & Fisone, G. (1999). Activation of dopamine D-2 receptors decrease DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience, 88, 1005-118.
33. Lorenz, K., Chase, T., Colburn, R. & Kopin, I. (1972). L-DOPA in parkinsonism. Neurology, 22, 688-696.
34. Loschmann, P.A., Smith, L.A., Lange, K.E., Jahnig, P., Jenner, P. & Marsden, C.D. (1991). Motor-activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets. Psychopharmacology, 105, 303-309.
35. Loschmann, P.A., Smith, L.A., Lange, K.W., Jahnig, P., Jenner, P. & Marsden, C.D. (1992). Motor-activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology, 109, 49-56.
36. Michaelides, M.R., Asin, K.E., Bianchi, B., Britton, D.R., Didomenico, S., Hodges, L., Hong, Y.F., Lin, C.W., Mikusa, J., Miller, T., Nikkel, A., Smith, L., Stashko, M., Williams, M., Jenner, P. & Shiosaki, K. (1995). A-86929 - a potent and selective dopamine (DA) D1 agonist with efficacy in rodent and primate models of Parkinsons-disease(PD). Abstracts of Papers of the American Chemical Society, 209, 83-MEDI.
37. 1 agonist that maintains behavioural efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431). J. Med. Chem., 95, 3445-3447.
38. Mierau, J. (1995). Pramipexole - a dopamine-receptor agonist for treatment of Parkinson's-disease. Clin. Neuropharmacol, 18, S-195-S206.
39. Mierau, J., Schneider, F., Ensinger, H., Chio, C., Lajiness, M. & Huff, R. (1995). Pramipexole binding and activation of cloned and expressed dopamine D-2, D-3 and D-4 receptors. Eur. J. Pharmacol. Mol. Pharmacol. Section, 290, 29-36.
40. Misu, Y., Okumura, Y., Goshima, Y., Yue, J.L. & Ueda, H. (1995). Nanomolar L-DOPA induces Ca2+-dependent and tetrodotoxin-sensitive release of glutamate from striata of conscious rat. J. Neurochem., 65, S154.
41. Nakamura, S., Goshima, Y., Yue, J.L. & Misu, Y. (1992). Transmitter-like basal and K +-evoked released of 3,4-dihydroxyphenylalanine from the striatum in conscious rats studied by microdialysis. J. Neurochem., 58, 270-275.
42. Nakamura, S., Yue, J., Goshima, Y., Miyamae, T., Ueda, H. & Misu, Y. (1994). Non-effective doses of exogenously applied L-DOPA itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities in conscious rats. Neurosci. Lett., 170, 22-26.
43. Nakazoto, T. & Akiyama, A. (1989). Effect of exogenous L-DOPA on behavior in the rat: an in vivo voltammetric study. Brain Res., 490, 332-338.
44. Poewe, W.H., Rascol, O., Brooks, D.J., Brunt, E.R., Korczyn, A.D. & Stocchi, F. (1998). Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Movement Disorders, 13, 39-45.
45. Rascol, O. (1996). A double blind L-DOPA controlled study of ropinirole in de novo patients with Parkinson's disease. Movement Disorders. 11, 139, P510.
46. Rascol, O., Blin, O., Descombes, S., Soubrouilliard, C., Fabre, N., Viallet, F., Thalamas, C., Azulay, J.P., Lafnitzegger, K., Fredrick, E., Wright, S. & Nutt, J. (1997). ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology, 48, 32004.
47. Rascol, O., Brooks, D.J., Brunt, E.R., Korczyn, A.D. & Stocchi, F. (1998). Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Movement Disorders, 13, 39-45.
48. Reavill, C., Jenner, P. & Marsden, C.D. (1983). Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. Biochem. Pharmacol., 32, 865-870.
49. Robertson, G.S. & Robertson, H.A. (1987). D1 and D2 dopamine agonist synergism - Separate sites of actions. Trends Pharmacol. Sci., 8, 295-299.
50. Rose, S., Jenner, P. & Marsden, C.D. (1988). The effect of carbidopa on plasma and muscle levels of L-DOPA, dopamine, and their metabolites following L-DOPA administration to rats. Movement Disorders, 3, 117-125.
51. Rose, S., Jenner, P. & Marsden, C.D. (1991). Peripheral pharmacokinetic handling and matabolism of L-DOPA in the rat - the effect of route of administration and carbidopa pretreatment. J. Pharm. Pharmacol., 43, 325-330.
52. Rose, S., Nomoto, M., Jenner, P. & Marsden, C.D. (1989a). Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Bioch. Pharmacol., 38, 3677-3681.
53. Rose, S., Nomoto, M., Kelly, E., Kilpatrick, G., Jenner, P. & Marsden, C.D. (1989b). Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with dopaminergic neurotoxin MPTP. Neurosci. Lett., 101, 305-310. S
54. Shiosaki, K., Jenner, P. & Asin, K. (1995). ABT-431: The diacyl prodrug of A86929, a potent and selective dopamine D1 receptor agonist: In vitro characterisation and effects in animal models of Parkinson's disease. J. Pharmacol. Exp. Therapeut., 276, 150-160.
55. Smith, L.A., Kebabian, J., Britton, D., Williams, M., Deninno, M., Jenner, P. & Marsden, C.D. (1992). A77636, a full D1 dopamine agonist, reverses MPTP-induced motor deficits in common marmosets. Br. J. Pharmacol., 107, 66-P 66.
56. Stocchi, F., Ruggieri, S., Carta, A., Ryatt, J., Quinn, N., Jenner, P., Marsden, C. & D'Agnoli, A. (1992). Intravenous boluses and continuous infussions of L-Dopa methyl-ester in fluctuating patients with Parkinsons-disease. Movement Disorders, 7, 249-256.
57. Treseder, S.A., Rose, S. & Jenner, P. (1999). The central DOPA decarboxylase inhibitor, NSD-1015, does not present L-DOPA-induced circling behaviour in 60HDA-lesioned rats. Br. J. Pharmacol., 127, 24.
58. Treseder, S.A., Smith, L., Jackson, M., Jenner, P. & Marsden, C.D. (1998). The actions of L-DOPA and dopamine agonsits following dopamine depletion in MPTP-treated common marmosets. Br. J. Pharmacol., 123, 251.
59. Trugman, J.M., James, C.L. & Wooten, G.F. (1991). D1/D2 dopamine receptor stimulation by L-DOPA A (C-14)-2-deoxyglucose autoradiographic study. Brain, 114, 1429-1440.
60. Ueki, A., Chong, P.N., Albanese, A., Rose, S., Chivers, J.K., Jenner, P. & Marsden, C.D. (1989). Further treatment with MPTP does not produce Parkinsonism in marmosets showing behavioral recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology, 28, 1089-1097.
61. Vermeulen, R.J., Drukarch, B., Sahadat, M.C.R., Goosen, C., Wolters, E.C., Stoof, J.C. (1994). The Dopamine-D-1 agonist Skf-81297 and the Dopamine-D-2 agonist Ly-171555 act synergistically to stimulate motor behavior of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Parkinsonian rhesus-monkeys. Movement Disorders, 6, 664-672.
62. Wu, M.B. & Brudzynski, S. (1995). Mesolimbic dopamine terminals and locomotor-activity induced from the subiculum. Neuroreport, 6, 1601-1604.
63. Wu, M., Brudzynski, S. & Mogensen, G. (1993). Functional interaction of dopamine and glutamate in the nucleus-accumbens in the regulation of locomotion. J. Physiol. Pharmacol., 71, 407-413.
64. Yue, J., Nakamura, S., Ueda, H. & Misu, Y. (1994). Endogenously released L-DOPA itself tonically functions to potentiate post-synaptic D2 receptor mediated locomotor activities of conscious rats. Neurosci. Lett., 170, 107-110.
65. Yung, K., Smith, A., Levey, A. & Bolam, J. (1996). Synaptic connections between spiny neurones of the direct and indirect pathways in the neostriatum of the rat: Evidence from dopamine receptor and neuropeptide immunostaining. Eur. J. Neurosci., 8, 861-869.